close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

2.120 -0.220 (-9.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,066,610
Open 2.090
Bid (Size) 2.050 (600)
Ask (Size) 2.060 (300)
Prev. Close 2.340
Today's Range 2.010 - 2.219
52wk Range 2.010 - 524.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
From Clearmind Medicine Inc.
Via GlobeNewswire

Performance

YTD
-89.3%
-89.3%
1 Month
-44.1%
-44.1%
3 Month
-82.9%
-82.9%
6 Month
-92.1%
-92.1%
1 Year
-99.5%
-99.5%

More News

Read More
News headline image
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
Via AB Newswire
Topics Artificial Intelligence Energy Intellectual Property
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
From Clearmind Medicine Inc.
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Clearmind Medicine Announces 1-for-10 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
From Clearmind Medicine Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?
Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
What exchange does Clearmind Medicine Inc. - Common Shares trade on?
Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
What is the current price of Clearmind Medicine Inc. - Common Shares?
The current price of Clearmind Medicine Inc. - Common Shares is 2.120
When was Clearmind Medicine Inc. - Common Shares last traded?
The last trade of Clearmind Medicine Inc. - Common Shares was at 07/07/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today